



PALM INTRANET

Day: Wednesday

Date: 6/18/2003

Time: 14:14:07

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

masuda

esteban

Search

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

(FILE 'HOME' ENTERED AT 13:51:47 ON 18 JUN 2003)

FILE 'BIOSIS, MEDLINE, CAPLUS, EMBASE, CANCERLIT' ENTERED AT 13:51:57 ON
18 JUN 2003

L1	9	TRAC1
L2	0	FLJ20456
L3	125145	LYMPHOCYTE ACTIVATION
L4	92105	ANTISENS?
L5	2	L1 AND L3
L6	2	L1 AND L4
L7	0	TRAC1 ANTIBODY

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:282593 CAPLUS

DOCUMENT NUMBER: 138:302661

TITLE: **Lymphocyte activation**

/migration-modulating nucleic acids and proteins for identifying diagnostics and therapeutics

INVENTOR(S): Chu, Peter; Li, Congfen; Liao, X. Charlene; Masuda, Esteban; Pardo, Jorge; Zhao, Haoran

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 126 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029277	A2	20030410	WO 2002-US31618	20021002
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2001-327212P P 20011003

AB The present invention relates to regulation of **lymphocyte activation** and migration. More particularly, the present invention is directed to nucleic acids encoding the nucleic acids and proteins listed in Figure 7, which are involved in modulation of **lymphocyte activation** and migration, e.g., A-raf-1, Lck, Zap70, Syk, PLC.gamma.1, PAG, SHP/PTP1C, CSK, nucleolin, SLAP, PAK2, **TRAC1**, TCPTP/PTPN2, EDG1, IL10-R.alpha., integrin.alpha.2, Enolase 1a, PRSM1, CLN2, P2X5b, 6PFKL, DUSP1, KIAA0251, GG2-1, GRB7, SH2-B, STAT1, TCF19, HFP101S, RERE, SudD, Ku70, SCAMP2, F1bulin-5, KIAA1228, Est from clone 2108068, vimentin, filamin A .alpha., centractin .alpha., moesin, TIMP3, and RNH. The invention further relates to methods for identifying and using agents, including small org. mols., antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, siRNA, and ribozymes, that modulate **lymphocyte activation** or migration; as well as to the use of expression profiles and compns. in diagnosis and therapy related to **lymphocyte activation** and suppression, and lymphocyte migration.

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:778621 CAPLUS

DOCUMENT NUMBER: 137:293541

TITLE: **TRAC1** polypeptides, polynucleotides and antibodies as modulators of **lymphocyte activation**

INVENTOR(S): Masuda, Esteban; Liao, X. Charlene; Zhao, Haoran; Chu, Peter; Pardo, Jorge

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 59 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002146747	A1	20021010	US 2001-998667	20011203
WO 2002081730	A2	20021017	WO 2002-US11205	20020408
WO 2002081730	A3	20030206		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-282432P P 20010406
US 2001-998667 A 20011203

AB The present invention relates to regulation of **lymphocyte activation**, esp. T **lymphocyte activation**.
More particularly, the present invention is directed to nucleic acids encoding **TRAC1**, a member of the ring finger protein family, which is involved in modulation of **lymphocyte activation**.
. The invention further relates to methods for identifying and using agents, including small org. mols., peptides, circular peptides, antibodies, lipids, antisense nucleic acids, and ribozymes, that modulate **lymphocyte activation** via modulation of **TRAC1**; as well as to the use of expression profiles and compns. in diagnosis and therapy related to **lymphocyte activation** and suppression. These agents are useful for diagnosis and therapy of cancer, inflammation, autoimmune disease, developmental abnormalities, neurodegenerative disease.

(FILE 'HOME' ENTERED AT 13:51:47 ON 18 JUN 2003)

FILE 'BIOSIS, MEDLINE, CAPLUS, EMBASE, CANCERLIT' ENTERED AT 13:51:57 ON
18 JUN 2003

L1 9 TRAC1
L2 0 FLJ20456
L3 125145 LYMPHOCYTE ACTIVATION
L4 92105 ANTISENS?
L5 2 L1 AND L3
L6 2 L1 AND L4

=> d ibib, abs L6 1-2

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:282593 CAPLUS

DOCUMENT NUMBER: 138:302661

TITLE: Lymphocyte activation/migration-modulating nucleic acids and proteins for identifying diagnostics and therapeutics

INVENTOR(S): Chu, Peter; Li, Congfen; Liao, X. Charlene; Masuda, Esteban; Pardo, Jorge; Zhao, Haoran

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 126 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029277	A2	20030410	WO 2002-US31618	20021002
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-327212P P 20011003

AB The present invention relates to regulation of lymphocyte activation and migration. More particularly, the present invention is directed to nucleic acids encoding the nucleic acids and proteins listed in Figure 7, which are involved in modulation of lymphocyte activation and migration, e.g., A-raf-1, Lck, Zap70, Syk, PLC.gamma.1, PAG, SHP/PTP1C, CSK, nucleolin, SLAP, PAK2, **TRAC1**, TCPTP/PTPN2, EDG1, IL10-R.alpha., integrin.alpha.2, Enolase 1a, PRSM1, CLN2, P2X5b, 6PFKL, DUSP1, KIAA0251, GG2-1, GRB7, SH2-B, STAT1, TCF19, HFP101S, RERE, SudD, Ku70, SCAMP2, Fibulin-5, KIAA1228, Est from clone 2108068, vimentin, filamin A .alpha., centractin .alpha., moesin, TIMP3, and RNH. The invention further relates to methods for identifying and using agents, including small org. mols., antibodies, peptides, cyclic peptides, nucleic acids, **antisense** nucleic acids, siRNA, and ribozymes, that modulate lymphocyte activation or migration; as well as to the use of expression profiles and compns. in diagnosis and therapy related to lymphocyte activation and suppression, and lymphocyte migration.

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:778621 CAPLUS

DOCUMENT NUMBER: 137:293541

TITLE: **TRAC1** polypeptides, polynucleotides and antibodies as modulators of lymphocyte activation
 INVENTOR(S): Masuda, Esteban; Liao, X. Charlene; Zhao, Haoran; Chu, Peter; Pardo, Jorge
 PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 59 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002146747	A1	20021010	US 2001-998667	20011203
WO 2002081730	A2	20021017	WO 2002-US11205	20020408
WO 2002081730	A3	20030206		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-282432P P 20010406
 US 2001-998667 A 20011203

AB The present invention relates to regulation of lymphocyte activation, esp. T lymphocyte activation. More particularly, the present invention is directed to nucleic acids encoding **TRAC1**, a member of the ring finger protein family, which is involved in modulation of lymphocyte activation. The invention further relates to methods for identifying and using agents, including small org. mols., peptides, circular peptides, antibodies, lipids, **antisense** nucleic acids, and ribozymes, that modulate lymphocyte activation via modulation of **TRAC1**; as well as to the use of expression profiles and compns. in diagnosis and therapy related to lymphocyte activation and suppression. These agents are useful for diagnosis and therapy of cancer, inflammation, autoimmune disease, developmental abnormalities, neurodegenerative disease.

L1 ANSWER 1 OF 9 BIOSIS CORYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 ACCESSION NUMBER: 2000:166998 BIOSIS
 DOCUMENT NUMBER: RREV200000166998
 TITLE: Antirestriction protein Ard (type C) encoded by IncW plasmid pSa has a high similarity to the "protein transport" domain of **TraC1** primase of promiscuous plasmid RP4.
 AUTHOR(S): Belogurov, Anatol A. (1); Delver, Eugene P.; Agafonova, Olga V.; Belogurova, Natali G.; Lee, Lan-Ying; Kado, Clarence I.
 CORRORATE SOURCE: (1) Department of Genetic Engineering, National Cardiological Research and Development Center, Moscow, 121552 Russia
 SOURCE: Journal of Molecular Biology., (March 3, 2000) Vol. 296, No. 4, pp. 969-977.
 ISSN: 0022-2836.
 DOCUMENT TYRE: Article
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 AB The IncW plasmid pSa contains the gene ard encoding an antirestriction function that is specific for type I restriction and modification systems. The nucleotide sequence of ard was determined and an appropriate polypeptide of about 33 kDa was identified in Escherichia coli T7 expression system. Analysis of deduced amino acid sequence of Ard encoded by pSa revealed that this protein has no significant similarities with the known Ard proteins (ArdA and ArdB types) except the "antirestriction" motif (14 amino acid residues in length) conserved for all known Ard proteins. This finding suggests that pSa Ard may be classified as a new type of Ard proteins which we designated ArdC. The remarkable feature of ArdC is that it has a high degree of similarity (about 38% identity) to the N-terminal region of RP4 **TraC1** primase which includes about 300 amino acid residues and seems to be essential for binding to the single-stranded DNA and **TraC1** protein transport to the recipient cells during the conjugal transfer of plasmid DNA. ArdC also binds to single-stranded DNA. In addition, this protein is able in vitro to protect the single-stranded but not double-stranded plasmid DNA against the activity of type II restriction endonuclease HhaI that cleaves both single and double-stranded DNA. We suggest that like **TraC1**, ArdC would be transported as a result of their interaction with the single-stranded DNA of transferred plasmid strand during conjugative passage through the cell envelope to the recipient bacterium. Such properties of ArdC protein might be useful to protect immediately the incoming single-stranded DNA from the host endonucleases.

L1 ANSWER 2 OF 9 MEDLINE
 ACCESSION NUMBER: 2000223510 MEDLINE
 DOCUMENT NUMBER: 20223510 PubMed ID: 10686096
 TITLE: Antirestriction protein Ard (Type C) encoded by IncW plasmid pSa has a high similarity to the "protein transport" domain of **TraC1** primase of promiscuous plasmid RR4.
 AUTHOR: Belogurov A A; Delver E R; Agafonova O V; Belogurova N G; Lee L Y; Kado C I
 CORRORATE SOURCE: Department of Genetic Engineering, National Cardiological Research and Development Center, Moscow, 121552, Russia.. belogurov@cardio.ru
 SOURCE: JOURNAL OF MOLECULAR BIOLOGY, (2000 Mar 3) 296 (4) 969-77.
 Journal code: 2985088R. ISSN: 0022-2836.
 RUB. COUNTRY: ENGLAND: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Rriority Journals
 OTHER SOURCE: GENBANK-AF143206
 ENTRY MONTH: 200004

ENTRY DATE: Entered STN: 20000421
Last Updated on STN: 20000421
Entered Medline: 20000413

AB The IncW plasmid pSa contains the gene ard encoding an antirestriction function that is specific for type I restriction and modification systems. The nucleotide sequence of ard was determined and an appropriate polypeptide of about 33 kDa was identified in Escherichia coli T7 expression system. Analysis of deduced amino acid sequence of Ard encoded by pSa revealed that this protein has no significant similarities with the known Ard proteins (ArdA and ArdB types) except the "antirestriction" motif (14 amino acid residues in length) conserved for all known Ard proteins. This finding suggests that pSa Ard may be classified as a new type of Ard proteins which we designated ArdC. The remarkable feature of ArdC is that it has a high degree of similarity (about 38 % identity) to the N-terminal region of RP4 **TraC1** primase which includes about 300 amino acid residues and seems to be essential for binding to the single-stranded DNA and **TraC1** protein transport to the recipient cells during the conjugal transfer of plasmid DNA. ArdC also binds to single-stranded DNA. In addition, this protein is able in vitro to protect the single-stranded but not double-stranded plasmid DNA against the activity of type II restriction endonuclease HhaI that cleaves both single and double-stranded DNA. We suggest that like **TraC1**, ArdC would be transported as a result of their interaction with the single-stranded DNA of transferred plasmid strand during conjugative passage through the cell envelope to the recipient bacterium. Such properties of ArdC protein might be useful to protect immediately the incoming single-stranded DNA from the host endonucleases.
Copyright 2000 Academic Press.

L1 ANSWER 3 OF 9 MEDLINE
ACCESSION NUMBER: 92297959 MEDLINE
DOCUMENT NUMBER: 92297959 PubMed ID: 1818755
TITLE: Gene organization and nucleotide sequence of the primase region of IncP plasmids RP4 and R751.
AUTHOR: Miele L; Strack B; Kruft V; Lanka E
CORPORATE SOURCE: Max-Planck-Institut fur Molekulare Genetik, Abteilung Schuster, Berlin, Germany.
SOURCE: DNA SEQUENCE, (1991) 2 (3) 145-62.
Journal code: 9107800. ISSN: 1042-5179.
PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: GENBANK-M65127; GENBANK-M65223; GENBANK-M65224;
GENBANK-M65235; GENBANK-S60919; GENBANK-S60920;
GENBANK-S89458; GENBANK-X59082; GENBANK-X59793;
GENBANK-X59794
ENTRY MONTH: 199207
ENTRY DATE: Entered STN: 19920731
Last Updated on STN: 19980206
Entered Medline: 19920723

AB The primase genes of RP4 are part of the primase operon located within the TraI region of this conjugative plasmid. The operon contains a total of seven transfer genes four of which (traA, B, C, D) are described here. Determination of the nucleotide sequence of the primase region confirmed the existence of an overlapping gene arrangement at the DNA primase locus (traC) with in-phase translational initiation signals. The traC gene encodes two acidic and hydrophilic polypeptide chains of 1061 (**TraC1**) and 746 (**TraC2**) amino acids corresponding to molecular masses of 116,721 and 81,647 Da. In contrast to RP4 the IncP beta plasmid R751 specifies four large primase gene products (192, 152, 135 and 83 kDa) crossreacting with anti-RP4 DNA primase serum. As shown by deletion analysis at least the 135 and 83 kDa polypeptides are two separate translational products that by analogy with the RP4 primases, arise from

in-phase translational initiation sites. Even the smallest primase gene products TraC2 (RP4) and TraC4 (R751) exhibit primase activity. Nucleotide sequencing of the R751 primase region revealed the existence of three in-phase traC translational initiation signals leading to the expression of gene products with molecular masses of 158,950 Da, 134,476 Da, and 80,759 Da. The 192 kDa primase polypeptide is suggested to be a fusion protein resulting from an in frame translational readthrough of the traD UGA stopcodon. Distinct sequence similarities can be detected between the TraC proteins of RP4 and R751 gene products TraC3 and TraC4 and in addition between the TraD proteins of both plasmids. The R751 traC3 gene contains a stretch of 507 bp which is unrelated to RP4 traC or any other RP4 TraI gene.

L1 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:282593 CAPLUS

DOCUMENT NUMBER: 138:302661

TITLE: Lymphocyte activation/migration-modulating nucleic acids and proteins for identifying diagnostics and therapeutics

INVENTOR(S): Chu, Peter; Li, Congfen; Liao, X. Charlene; Masuda, Esteban; Pardo, Jorge; Zhao, Haoran

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 126 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029277	A2	20030410	WO 2002-US31618	20021002
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2001-327212P P 20011003

AB The present invention relates to regulation of lymphocyte activation and migration. More particularly, the present invention is directed to nucleic acids encoding the nucleic acids and proteins listed in Figure 7, which are involved in modulation of lymphocyte activation and migration, e.g., A-raf-1, Lck, Zap70, Syk, PLC.gamma.1, PAG, SHP/PTP1C, CSK, nucleolin, SLAP, PAK2, **TRAC1**, TCPTP/PTPN2, EDG1, IL10-R.alpha., integrin.alpha.2, Enolase 1a, PRSM1, CLN2, P2X5b, 6PFKL, DUSP1, KIAA0251, GG2-1, GRB7, SH2-B, STAT1, TCF19, HFP101S, RERE, SudD, Ku70, SCAMP2, Fibulin-5, KIAA1228, Est from clone 2108068, vimentin, filamin A .alpha., contractin .alpha., moesin, TIMP3, and RNH. The invention further relates to methods for identifying and using agents, including small org. mols., antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, siRNA, and ribozymes, that modulate lymphocyte activation or migration; as well as to the use of expression profiles and compns. in diagnosis and therapy related to lymphocyte activation and suppression, and lymphocyte migration.

L1 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:778621 CAPLUS

DOCUMENT NUMBER: 137:293541

TITLE: **TRAC1** polypeptides, polynucleotides and antibodies as modulators of lymphocyte activation
 INVENTOR(S): Masuda, Esteban; Liao, X. Charlene; Zhao, Haoran; Chu, Peter; Pardo, Jorge
 PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 59 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002146747	A1	20021010	US 2001-998667	20011203
WO 2002081730	A2	20021017	WO 2002-US11205	20020408
WO 2002081730	A3	20030206		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-282432P P 20010406
 US 2001-998667 A 20011203

AB The present invention relates to regulation of lymphocyte activation, esp. T lymphocyte activation. More particularly, the present invention is directed to nucleic acids encoding **TRAC1**, a member of the ring finger protein family, which is involved in modulation of lymphocyte activation. The invention further relates to methods for identifying and using agents, including small org. mols., peptides, circular peptides, antibodies, lipids, antisense nucleic acids, and ribozymes, that modulate lymphocyte activation via modulation of **TRAC1**; as well as to the use of expression profiles and compns. in diagnosis and therapy related to lymphocyte activation and suppression. These agents are useful for diagnosis and therapy of cancer, inflammation, autoimmune disease, developmental abnormalities, neurodegenerative disease.

L1 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:809633 CAPLUS

DOCUMENT NUMBER: 134:69541

TITLE: Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R

AUTHOR(S): Amler, Lukas C.; Agus, David B.; LeDuc, Carrie; Sapinoso, M. Lisa; Fox, William D.; Kern, Suzanne; Lee, Dori; Wang, Vivian; Leysens, Maurice; Higgins, Brian; Martin, Jason; Gerald, William; Dracopoli, Nicholas; Cordon-Cardo, Carlos; Scher, Howard I.; Hampton, Garret M.

CORPORATE SOURCE: Genos Biosciences Incorporated, La Jolla, CA, 92037, USA

SOURCE: Cancer Research (2000), 60(21), 6134-6141
 CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Treatment of metastatic prostate cancer with androgen-ablation often elicits dramatic tumor regressions, but the response is rarely complete, making clin. recurrence inevitable with time. To gain insight into

therapy-related progression, changes in gene expression that occurred following androgen-deprivation of an androgen-dependent prostate tumor xenograft, CWR22, and the emergence of an androgen-independent tumor, CWR22-R, were monitored using microarray anal. Androgen-deprivation resulted in growth arrest of CWR22 cells, as evidenced by decreased expression of genes encoding cell cycle components and basal cell metab., respiration and transcription, and the induced expression of putative neg. regulatory genes that may act to sustain cells in a nonproliferative state. Evolution of androgen-independent growth and proliferation, represented by CWR22-R, was assocd. with a reentry into active cell cycle and the up-regulation of several genes that were expressed at low levels or absent in the androgen-dependent tumor. Androgen repletion to mice bearing androgen-independent CWR22-R tumors induced, augmented, or repressed the expression of a no. of genes. Expression of two of these genes, the calcium-binding protein S100P and the FK-506-binding protein FKBP51, was decreased following androgen-deprivation, subsequently reexpressed in CWR22-R at levels comparable with CWR22, and elevated further upon treatment with androgens. The dysregulated behavior of these genes is analogous to other androgen-dependent genes, e.g., prostate-specific antigen and human kallikrein 2, which are commonly reexpressed in androgen-independent disease in the absence of androgens. Other androgen-responsive genes whose expression decreased during androgen-deprivation and whose expression remained decreased in CWR22 were also identified in CWR22-R. These results imply that evolution to androgen-independence is due, in part, to reactivation of the androgen-response pathway in the absence of androgens, but that this reactivation is probably incomplete.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:127496 CAPLUS

DOCUMENT NUMBER: 133:39024

TITLE: Antirestriction Protein Ard (Type C) Encoded by IncW Plasmid pSa has a High Similarity to the "Protein Transport" Domain of **TraC1** Primase of Promiscuous Plasmid RP4

AUTHOR(S): Belogurov, Anatol A.; Delver, Eugene P.; Agafonova, Olga V.; Belogurova, Natali G.; Lee, Lan-Ying; Kado, Clarence I.

CORPORATE SOURCE: Department of Genetic Engineering, National Cardiological Research and Development Center, Moscow, 121552, Russia

SOURCE: Journal of Molecular Biology (2000), 296(4), 969-977
CODEN: JMOBAK; ISSN: 0022-2836

PUBLISHER: Academic Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The IncW plasmid pSa contains the gene ard encoding an antirestriction function that is specific for type I restriction and modification systems. The nucleotide sequence of ard was detd. and an appropriate polypeptide of about 33 kDa was identified in Escherichia coli T7 expression system. Anal. of deduced amino acid sequence of Ard encoded by pSa revealed that this protein has no significant similarities with the known Ard proteins (ArdA and ArdB types) except the "antirestriction" motif (14 amino acid residues in length) conserved for all known Ard proteins. This finding suggests that pSa Ard may be classified as a new type of Ard proteins which we designated ArdC. The remarkable feature of ArdC is that it has a high degree of similarity (about 38 % identity) to the N-terminal region of RP4 **TraC1** primase which includes about 300 amino acid residues and seems to be essential for binding to the single-stranded DNA and **TraC1** protein transport to the recipient cells during the conjugal transfer of plasmid DNA. ArdC also binds to single-stranded DNA. In addn., this protein is able in vitro to protect the single-stranded but

not double-stranded plasmid DNA against the activity of type II restriction endonuclease HhaI that cleaves both single and double-stranded DNA. We suggest that like **TraC1**, ArdC would be transported as a result of their interaction with the single-stranded DNA of transferred plasmid strand during conjugative passage through the cell envelope to the recipient bacterium. Such properties of ArdC protein might be useful to protect immediately the incoming single-stranded DNA from the host endonucleases. (c) 2000 Academic Press.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:206283 CAPLUS

DOCUMENT NUMBER: 118:206283

TITLE: Gene organization and nucleotide sequence of the primase region of IncP plasmids RP4 and R751

AUTHOR(S): Miele, Lucio; Strack, Bettina; Kruff, Volker; Lanka, Erich

CORPORATE SOURCE: Abt. Schuster, Max-Planck-Inst. Mol. Genet., Berlin, D-1000/33, Germany

SOURCE: DNA Sequence (1991), 2(3), 145-62
CODEN: DNSEES; ISSN: 1042-5179

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The primase genes of RP4 are part of the primase operon located within the TraI region of this conjugative plasmid. The operon contains a total of 7 transfer genes, 4 of which (traA, B, C, D) are described here. Detn. of the nucleotide sequence of the primase region confirmed the existence of an overlapping gene arrangement at the DNA primase locus (traC) with in-phase translational initiation signals. The traC gene encodes 2 acidic and hydrophilic polypeptide chains of 1061 (**TraC1**) and 746 (TraC2) amino acids corresponding to mol. masses of 116,721 and 81,647 Da. In contrast to RP4, the IncP.beta. plasmid R751 specifies 4 large primase gene products (192, 152, 135 and 83 kDa) crossreacting with anti-RP4 DNA primase serum. As shown by deletion anal., at least the 135 and 83 kDa polypeptides are 2 sep. translational products that by analogy with the RP4 primases, arise from in-phase translational initiation sites. Even the smallest primase gene products TraC2 (RP4) and TraC4 (R751) exhibit primase activity. Nucleotide sequencing of the R751 primase region revealed the existence of 3 in-phase traC translational initiation signals leading to the expression of gene products with mol. masses of 158,950 Da, 134,476 Da, and 80,759 Da. The 192 kDa primase polypeptide is suggested to be a fusion protein resulting from an in-frame translational readthrough of the traD UGA stop codon. Distinct sequence similarities can be detected between the TraC proteins of RP4 and TraC3 and TraC4 proteins of R751 and, in addn., between the TraD proteins of both plasmids. The R751 traC3 gene contains a stretch of 507 bp which is unrelated to RP4 traC or any other RP4 TraI gene.

L1 ANSWER 9 OF 9 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2000326979 EMBASE

TITLE: Antirestriction protein ard (type C) encoded by IncW plasmid pSa has a high similarity to the 'protein transport' domain of **TraC1** primase of promiscuous plasmid RP4.

AUTHOR: Belogurov A.A.; Delver E.P.; Agafonova O.V.; Belogurova N.G.; Lee L.-Y.; Kado C.I.

CORPORATE SOURCE: A.A. Belogurov, Department of Genetic Engineering, Natl. Cardiological Res./Devt. Ctr., Moscow 121552, Russian Federation. belogurov@cardio.ru

SOURCE: Journal of Molecular Biology, (3 Mar 2000) 296/4 (969-977).
Refs: 34

ISSN: 0022-2836 CODEN: JMOBAK

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English

AB The IncW plasmid pSa contains the gene ard encoding an antirestriction function that is specific for type I restriction and modification systems. The nucleotide sequence of ard was determined and an appropriate polypeptide of about 33 kDa was identified in Escherichia coli T7 expression system. Analysis of deduced amino acid sequence of Ard encoded by pSa revealed that this protein has no significant similarities with the known Ard proteins (ArdA and ArdB types) except the 'antirestriction' motif (14 amino acid residues in length) conserved for all known Ard proteins. This finding suggests that pSa Ard may be classified as a new type of Ard proteins which we designated ArdC. The remarkable feature of ArdC is that it has a high degree of similarity (about 38% identity) to the N-terminal region of RP4 **TraC1** primase which includes about 300 amino acid residues and seems to be essential for binding to the single-stranded DNA and **TraC1** protein transport to the recipient cells during the conjugal transfer of plasmid DNA. ArdC also binds to single-stranded DNA. In addition, this protein is able in vitro to protect the single-stranded but not double-stranded plasmid DNA against the activity of type II restriction endonuclease HhaI that cleaves both single and double-stranded DNA. We suggest that like **TraC1**, ArdC would be transported as a result of their interaction with the single-stranded DNA of transferred plasmid strand during conjugative passage through the cell envelope to the recipient bacterium. Such properties of ArdC protein might be useful to protect immediately the incoming single-stranded DNA from the host endonucleases. (C) 2000 Academic Press.

WEST Search History

DATE: Wednesday, June 18, 2003

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
L6	L1 and L4	4	L6
L5	L1 and L3	2	L5
L4	antisens\$3	33164	L4
L3	lymphocyte activation	1628	L3
L2	FLJ20456	1	L2
L1	TRAC1	7	L1

END OF SEARCH HISTORY

Print

[illegible]

└ 3. Document ID: US 20030027137 A1

L1: Entry 3 of 7

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027137
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027137 A1

TITLE: Novel nuclear receptor corepressor molecules and uses therefor

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chen, J. Don	Westboro	MA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/358, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	PubC
Draw Desc	Image										

└ 4. Document ID: US 20020146747 A1

L1: Entry 4 of 7

File: PGPB

Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146747
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020146747 A1

TITLE: TRAC1: modulators of lymphocyte activation

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Masuda, Esteban	Menlo Park	CA	US	
Liao, X. Charlene	Palo Alto	CA	US	
Zhao, Haoran	Foster City	CA	US	
Chu, Peter	San Francisco	CA	US	
Pardo, Jorge	San Francisco	CA	US	

US-CL-CURRENT: 435/7.21; 435/18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	PubC
Draw Desc	Image										

└ 5. Document ID: US 5748398 A

L1: Entry 5 of 7

File: USPT

May 5, 1998

US-PAT-NO: 5748398
DOCUMENT-IDENTIFIER: US 5748398 A

TITLE: Method for writing servo signals onto a magnetic disk and magnetic disk drive equipped with magnetic disk(s) having servo pattern recorded by the method

DATE-ISSUED: May 5, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Seo; Yosuke	Sagamihara			JP

US-CL-CURRENT: 360/51; 360/48, 360/77.08

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMIC
Draw Desc	Image									

┘ 6. Document ID: US 4338661 A

L1: Entry 6 of 7

File: USPT

Jul 6, 1982

US-PAT-NO: 4338661

DOCUMENT-IDENTIFIER: US 4338661 A

TITLE: Conditional branch unit for microprogrammed data processor

DATE-ISSUED: July 6, 1982

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tredennick; Harry L.	Austin	TX		
Gunter; Thomas G.	Austin	TX		

US-CL-CURRENT: 712/234; 712/245

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMIC
Draw Desc	Image									

┘ 7. Document ID: US 20020146747 A1 WO 200281730 A2

L1: Entry 7 of 7

File: DWPI

Oct 10, 2002

DERWENT-ACC-NO: 2003-174172

DERWENT-WEEK: 200317

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Identification of T lymphocyte-activation inhibiting compound, e.g. antibody, by contacting the compound with TRAC1 polypeptide or its fragment encoded by nucleic acid

INVENTOR: CHU, P; LIAO, X C ; MASUDA, E ; PARDO, J ; ZHAO, H ; LI, C

PRIORITY-DATA: 2001US-282432P (April 6, 2001), 2001US-0998667 (December 3, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020146747 A1	October 10, 2002		059	G01N033/567
WO 200281730 A2	October 17, 2002	E	000	C12Q000/00

INT-CL (IPC): C12 Q 0/00; C12 Q 1/34; G01 N 33/567

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	None
Draw	Desc	Image								

[Generate Collection](#)[Print](#)

Term	Documents
TRAC1	7
TRAC1S	0
TRAC1.USPT,PGPB,JPAB,EPAB,DWPI.	7
(TRAC1).USPT,PGPB,JPAB,EPAB,DWPI.	7

Display Format: -[Change Format](#)[Previous Page](#)[Next Page](#)

WEST

Generate Collection

Print

Search Results - Record(s) 1 through 1 of 1 returned.

1. Document ID: US 20020146747 A1

Oct 10, 2002

File: PGPB

L2: Entry 1 of 1

PGPUB-DOCUMENT-NUMBER: 20020146747

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020146747 A1

TITLE: TRAC1: modulators of lymphocyte activation

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME

Masuda, Esteban

Liao, X. Charlene

Zhao, Haoran

Chu, Peter

Pardo, Jorge

CITY

Menlo Park

Palo Alto

Foster City

San Francisco

San Francisco

STATE

CA

CA

CA

CA

CA

COUNTRY

US

US

US

US

US

RULE-47

US-CL-CURRENT: 435/7.21; 435/18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw	Desc	Image							

KIND

Generate Collection

Print

Term	Documents
FLJ20456	1
FLJ20456S	0
FLJ20456.USPT,PGPB,JPAB,EPAB,DWPI.	1
(FLJ20456).USPT,PGPB,JPAB,EPAB,DWPI.	1

Display Format:

Change Format

[Previous Page](#)[Next Page](#)

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 2 of 2 returned.****1. Document ID: US 20020146747 A1**

L5: Entry 1 of 2

File: PGPB

Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146747
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020146747 A1

TITLE: TRAC1: modulators of lymphocyte activation

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Masuda, Esteban	Menlo Park	CA	US	
Liao, X. Charlene	Palo Alto	CA	US	
Zhao, Haoran	Foster City	CA	US	
Chu, Peter	San Francisco	CA	US	
Pardo, Jorge	San Francisco	CA	US	

US-CL-CURRENT: 435/7.21; 435/18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FWMC
Draw Desc	Image										

2. Document ID: US 20020146747 A1 WO 200281730 A2

L5: Entry 2 of 2

File: DWPI

Oct 10, 2002

DERWENT-ACC-NO: 2003-174172
DERWENT-WEEK: 200317
COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Identification of T lymphocyte-activation inhibiting compound, e.g. antibody, by contacting the compound with TRAC1 polypeptide or its fragment encoded by nucleic acid

INVENTOR: CHU, P; LIAO, X C ; MASUDA, E ; PARDO, J ; ZHAO, H ; LI, C

PRIORITY-DATA: 2001US-282432P (April 6, 2001), 2001US-0998667 (December 3, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020146747 A1	October 10, 2002		059	G01N033/567
WO 200281730 A2	October 17, 2002	E	000	C12Q000/00

INT-CL (IPC): C12 Q 0/00; C12 Q 1/34; G01 N 33/567

Full	Title	Citation	Front	Reclaim	Classification	Date	Reference	Sequences	Attachments	Claims	End
Draw Desc	Image										

[Generate Collection](#)[Print](#)

Term	Documents
(1 AND 3).USPT,PGPB,JPAB,EPAB,DWPI.	2
(L1 AND L3).USPT,PGPB,JPAB,EPAB,DWPI.	2

Display Format: -[Change Format](#)[Previous Page](#)[Next Page](#)

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 4 of 4 returned.****1. Document ID: US 20030092009 A1**

L6: Entry 1 of 4

File: PGPB

May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092009
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030092009 A1

TITLE: Profiling tumor specific markers for the diagnosis and treatment of
neoplastic disease

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Palm, Kaia	Santa Monica	CA	US	

US-CL-CURRENT: 435/6; 435/287.2, 435/7.23

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

[FIND](#)**2. Document ID: US 20030027137 A1**

L6: Entry 2 of 4

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027137
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027137 A1

TITLE: Novel nuclear receptor corepressor molecules and uses therefor

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chen, J. Don	Westboro	MA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/358, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

[FIND](#)**3. Document ID: US 20020146747 A1**

L6: Entry 3 of 4

File: PGPB

Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146747
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020146747 A1

TITLE: TRAC1: modulators of lymphocyte activation

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Masuda, Esteban	Menlo Park	CA	US	
Liao, X. Charlene	Palo Alto	CA	US	
Zhao, Haoran	Foster City	CA	US	
Chu, Peter	San Francisco	CA	US	
Pardo, Jorge	San Francisco	CA	US	

US-CL-CURRENT: 435/7.21; 435/18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	None
Draw Desc	Image									

4. Document ID: US 20020146747 A1 WO 200281730 A2

L6: Entry 4 of 4

File: DWPI

Oct 10, 2002

DERWENT-ACC-NO: 2003-174172

DERWENT-WEEK: 200317

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Identification of T lymphocyte-activation inhibiting compound, e.g. antibody, by contacting the compound with TRAC1 polypeptide or its fragment encoded by nucleic acid

INVENTOR: CHU, P; LIAO, X C ; MASUDA, E ; PARDO, J ; ZHAO, H ; LI, C

PRIORITY-DATA: 2001US-282432P (April 6, 2001), 2001US-0998667 (December 3, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020146747 A1	October 10, 2002		059	G01N033/567
WO 200281730 A2	October 17, 2002	E	000	C12Q000/00

INT-CL (IPC): C12 Q 0/00; C12 Q 1/34; G01 N 33/567

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	None
Draw Desc	Image									

Generate Collection

Print

Term	Documents
(1 AND 4).USPT,PGPB,JPAB,EPAB,DWPI.	4
(L1 AND L4).USPT,PGPB,JPAB,EPAB,DWPI.	4

Display Format: [Change Format](#)

[Previous Page](#)

[Next Page](#)

Gibbs, Terra

From: Gibbs, Terra
Sent: Wednesday, June 18, 2003 12:45 PM
To: STIC-Biotech/ChemLib
Subject: Sequence search request...

Could you please do a regular search of SEQ ID NO: 1 of USSN 09/998667?

Thank You!

Terra Gibbs
AU 1635
306-3221
Mailbox: 11E12

Gibbs, Terra

From: Gibbs, Terra
Sent: Wednesday, June 18, 2003 12:46 PM
To: STIC-Biotech/ChemLib
Subject: Sequence search request...

Could you please do a regular search of SEQ ID NO: 2 of USSN 09/998667?

Thank You!

Terra Gibbs
AU 1635
306-3221
Mailbox: 11E12